PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients

NCT03251313 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

COMBINATION_PRODUCT: JS001 120mg+GP
COMBINATION_PRODUCT: JS001 240mg+GP
COMBINATION_PRODUCT: JS001 480mg+GP
COMBINATION_PRODUCT: GP followed by JS001

Sponsor

Fudan University